High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: Its potential use in the diagnosis of liver neoplasms

Journal of Gastroenterology

Volumn 38, Issue 12, 2003, Pages 1144-1149

  Abe, Nobutsugu ^a   Watanabe, Takashi ^a   Izumisato, Yumi ^a   Suzuki, Yutaka ^a   Masaki, Tadahiko ^a   Mori, Toshiyuki ^a   Sugiyama, Masanori ^a   Fusco, Alfredo ^b   Atomi, Yutaka ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cholangiocarcinoma; Diagnostic marker; Hepatocellular carcinoma; High mobility group A; HMGA1; Immunohistochemical analysis; Metastatic adenocarcinoma to the liver

Indexed keywords

HIGH MOBILITY GROUP A PROTEIN;

ADENOCARCINOMA; ANTIBODY SPECIFICITY; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; HMGA PROTEINS; HUMANS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS;

EID: 1642421868     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1221-9     Document Type: Article

References (40)

1. Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMGI(Y). J Biol Chem 1988; 263:18338-42.
2. Manfioletti G, Giancotti V, Bandiera A, Buratti E, Sautiewre P, Cary P, et al. cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res 1991;19:6793-7.
3. Reeves R, Nissen MS. The AT DNA binding domain of mammalian high mobility group I chromosomal proteins: a novel peptide motif for recognizing DNA structure. J Biol Chem 1990;265: 8576-82.
4. Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. In: Cohn WE, Moldave K, editors. Progress in nucleic acid research and molecular biology, vol. 54. San Diego: Academic; 1996;35-100.
5. Du W, Thanos D, Maniatis T. Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements. Cell 1993;74:887-98.
6. Falvo JV, Thanos D, Maniatis T. Reversal of intrinsic DNA bends in the IFN-β gene enhancer by transcription factors and the architectural protein HMGI(Y). Cell 1995;83:1101-11.
7. Maher JF, Nathans D. Multivalent DNA-binding properties of the HMG-I proteins. Proc Natl Acad Sci U S A 1995; 93:6716-20.
8. Strick R, Laemmli UK. SARs are cis DNA elements of chromosome dynamics: synthesis of SAR repressor protein. Cell 1995;83: 1137-48.
9. Thanos D, Maniatis T. The high mobility group protein HMGI(Y) is required for NF-κB dependent virus induction of the human IFN-β gene. Cell 1992;71:777-89.
10. Thanos D, Maniatis T. Virus induction of human IFN-β gene expression requires the assembly of an enhancesome. Cell 1995; 83:1091-100.
11. Wolffe AP. Architectural transcription factors. Science 1994;264: 1100-1.
12. Lewis H, Kaszubska W, Delamarter JF, Whelan J. Cooperativity between two NF-κB complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine induced expression of the E-selectin promoter. Mol Cell Biol 1994;14:5701-9.
13. Chuvpilo S, Schomberg C, Gerwig R, Heinfling A, Reeves R, Grummt F, et al. Multiple closely-linked NFAT/octamer and HMGI(Y) binding sites are part of the interleukin-4 promoter. Nucleic Acids Res 1993;21:5694-704.
14. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-4.
15. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, et al. High level expression of the HMGI(Y) gene during embryonic development. Oncogene 1996;13:2439-46.
16. Chiappetta G, Bandiera A, Berlingieri MT, Visconti R, Manfioletti G, Battista S, et al. The expression of the high mobility group HMGI(Y) proteins correlates with the malignant phenotype of human thyroid neoplasm. Oncogene 1995;10:1307-14.
17. Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, et al. Detection of high mobility group I(Y) HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58:4193-8.
18. Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HFM, Debruyne FMJ, et al. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res 1993;53:5512-6.
19. Tamimi Y, van der Poel HG, Karthaus HFM, Debruyne FMJ, Schalken JA. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer 1996;74:573-8.
20. Bandiera A, Bonifacio D, Manfioletti G, Mantovani F, Rustighi A, Zanconati F, et al. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 1998;58:426-31.
21. Fedele M, Bandiera A, Chiappetta G, Battista S, Viglietto G, Visconti R, et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 1996;56:1896-901.
22. Abe N, Watanabe T, Sugiyama M, Uchimura H, Chiapetta G, Fusco A, et al. Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res 1999;59:1169-74.
23. Chiappetta G, Manfioletti G, Pentimalli F, Abe N, Di Bonito M, Vento MT, et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 2001;15:147-51.
24. Kim DH, Park YS, Park CJ, Son KC, Nam ES, Shin HS, et al. Expression of the HMGI(Y) gene in human colorectal cancer. Int J Cancer 1999;84:376-80.
25. Abe N, Watanabe T, Masaki T, Mori T, Sugiyama M, Uchimura H, et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) (HMGI(Y)) proteins. Cancer Res 2000;60:3117-22.
26. Abe N, Watanabe T, Izumisato Y, Masaki T, Mori T, Sugiyama M, et al. Diagnostic significance of high mobility group I(Y) protein expression in intraductal papillary mucinous tumors of the pancreas. Pancreas 2002;25:198-204.
27. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, et al. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000;20:5490-502.
28. Ram TG, Reeves R, Hosiek HL. Elevated high mobility group I(Y) gene expression is associated with progressive transformation of mouse mammary epithelial cells. Cancer Res 1993;53: 2655-60.
29. Bussemakers MJG, Van de Ven WJM, Schalken JA. Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. Cancer Res 1991;51:606-11.
30. Balcom JH 4th, Keck T, Warshaw AL, Antoniu B, Graeme-Cook F, Fernandez-del Castill C. Telomerase activity in periampullary tumors correlates with aggressive malignancy. Ann Surg 2001;234: 344-51.
31. Sato N, Maehara N, Mizumoto K, Nagai E, Yasoshima T, Hirata K, et al. Telomerase activity of cultured human pancreatic carcinoma cell lines correlates with their potential for migration and invasion. Cancer 2001;91:496-504.
32. Ganjei P, Nadji M, Albores-Saavedra J, Morales AR. Histologic markers in primary and metastatic tumors of the liver. Cancer 1988;62:1994-8.
33. Brumm C, Schulze C, Charles K, Morohoshi T, Klöppel G. The significance of alpha-fetoprotein and other tumor markers in differential immunocytochemistry of primary liver tumors. Histopathology 1989;14:503-13.
34. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 1987;12: 187-97.
35. Pastolero GC, Wakabayashi T, Oka T, Mori S. Tissue polypeptide antigen. A marker antigen differentiating cholangiolar tumors from other hepatic tumors. Am J Clin Pathol 1987;87:168-73.
36. y in the differential diagnosis of cholangiocarcinoma and hepatocellular carcinoma. Arch Pathol Lab Med 1989;113:139-42.
37. Proca DM, Niemann TH, Porcell AI, DeYoung BR. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Appl Immunohistochem Mol Morphol 2000;8:120-5.
38. Grem JL. Current treatment approaches in colorectal cancer. Semin Oncol 1991;18:17-26.
39. Topf N, Worgall S, Hackett NR, Crystal RG. Regional "prodrug" gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Ther 1998;5:507-13.
40. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A 2000;97:4256-61.